The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1293
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension

Aliskiren (Tekturna – Novartis), the first direct renin inhibitor for treatment of hypertension,1 has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT – Novartis). Many angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are also available in fixed-dose combinations with hydrochlorothiazide (HCTZ).

MECHANISM OF ACTION — Aliskiren binds and inhibits the catalytic site of renin, thereby preventing release of angiotensin I and reducing serum concentrations of angiotensin I, angiotensin II and aldosterone.2 Unlike ACE inhibitors and ARBs, which increase both plasma renin concentrations (PRC) and activity (PRA), aliskiren increases PRC, but suppresses PRA.3 HCTZ can cause secondary activation of the renin-angiotensin-aldosterone system (RAAS) and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1293
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian